MASH prevalence and the FGF21 therapeutic rationale

MASH (metabolic dysfunction-associated steatohepatitis) is the progressive inflammatory form of MASLD, a chronic liver condition affecting approximately 38% of the global population — yet as of 2024, only two FDA-approved treatments exist for the disease. This disproportion between disease burden and therapeutic options defines the commercial and scientific imperative behind FGF21-based drug development. MASH can progress through a spectrum from simple hepatic steatosis to fibrosis, cirrhosis, and hepatocellular carcinoma, with patients at the fibrotic end of the spectrum representing the highest unmet medical need and the most commercially attractive regulatory target.

FGF21 (fibroblast growth factor 21) sits at the intersection of these unmet needs. According to the academic literature, FGF21 is a hepatokine with a central role in regulating energy metabolism and sensitizing cells to insulin — two of the core pathophysiological drivers of MASH. As documented in Nature-adjacent hepatology research, FGF21's pathway directly modulates hepatic steatosis and lipid metabolism, making it a mechanistically grounded target rather than a surrogate endpoint play. The challenge with native FGF21 as a drug candidate has always been its short circulating half-life, which limits its therapeutic utility in a chronic disease requiring sustained pathway activation. The engineered FGF21 analog strategy — exemplified by efruxifermin — was developed specifically to address this limitation.

The high global prevalence, the scarcity of approved treatments, and the direct mechanistic link between FGF21 signaling and MASH pathophysiology collectively establish why FGF21-based assets have attracted substantial R&D investment and strategic acquisition interest. According to WHO estimates, liver disease is among the leading causes of non-communicable disease mortality globally, further reinforcing the public health and commercial scale of this therapeutic category.

How efruxifermin overcomes native FGF21's pharmacological limitations

Efruxifermin solves the core pharmacological problems of native FGF21 through a precisely engineered fusion protein architecture that addresses two distinct molecular barriers: sequestration by binding proteins and rapid enzymatic degradation. Both barriers are explicitly named in Akero Therapeutics' patent claims as the scientific basis for the molecule's design, making the IP estate directly traceable to the therapeutic mechanism.

The first molecular barrier addressed is FGFBP3 (FGF binding protein 3), which competitively sequesters endogenous FGF21 and limits its bioavailability. Akero's patents explicitly claim that the efruxifermin variant polypeptide exhibits "decreased binding to FGFBP3 and other FGF binding proteins" — a structural modification that liberates FGF21 receptor signaling from competitive inhibition. This is not a generic engineering choice; the FGFBP3 interaction is identified in patent claims as a specific, named pharmacological barrier, suggesting that Akero's medicinal chemistry was guided by a detailed understanding of the endogenous regulatory landscape.

The second barrier is PREP (prolyl endopeptidase), an endopeptidase that cleaves and inactivates native FGF21 in circulation. The efruxifermin variant exhibits "reduced susceptibility to cleavage by prolyl endopeptidase (PREP) and other endopeptidases," as documented in the core patent filings. Combined with the Fc fusion's half-life extension via FcRn-mediated recycling, these two modifications transform a pharmacologically active but practically limited endogenous hormone into a clinically viable weekly-dosing biologic.

This multi-component engineering approach is also reflected in the breadth of Akero's patent claims. Rather than protecting a single molecule, the patents claim variant polypeptides defined by "one or more mutations compared to a reference polypeptide" — a claim architecture that creates a wide exclusionary zone around the core efruxifermin scaffold while also covering next-generation variants. According to EPO patent practice, such functionally defined claims covering a class of molecules with shared properties (reduced binding partner affinity, reduced protease susceptibility) are among the most defensible in the biologic IP landscape when backed by demonstrated structure-activity data.

BALANCED Phase 2b trial: efficacy and safety evidence in MASH with compensated cirrhosis

The BALANCED Phase 2b trial — a randomized, double-blind, placebo-controlled study — provides the primary clinical validation for efruxifermin in MASH, specifically in the high-unmet-need population of patients with compensated cirrhosis (F4 fibrosis). Published in the Journal of Hepatology in 2024, the trial results establish both the efficacy signal and the safety profile that underpin efruxifermin's regulatory and commercial positioning.

"Efruxifermin significantly improved fibrosis in MASH participants with compensated cirrhosis, representing a potential treatment for a population with high unmet need."

The primary efficacy endpoint was histological improvement — defined as ≥1 stage improvement in fibrosis without worsening of NASH — a regulatory-grade endpoint aligned with FDA guidance for MASH drug development. Both active doses met this endpoint with statistical significance (p<0.05 for both) at the 28-week timepoint. The placebo response rate of 20% is consistent with the MASH literature, making the absolute response rates of 39% (28 mg) and 41% (50 mg) and the adjusted treatment differences of +22 and +24 percentage points, respectively, clinically meaningful signals.

The near-identical efficacy between the 28 mg and 50 mg doses is a notable finding from the retrieved data. This dose-equivalence at the primary endpoint suggests that efruxifermin's fibrosis-reversing activity may plateau at a relatively low dose, which has implications for dose selection in the Phase 3 SYNCHRONY programme and for the commercial formulation strategy — a lower effective dose typically translates to a more favourable manufacturing cost of goods and a potentially wider therapeutic window.

On safety, the retrieved data identifies nausea and vomiting as the most frequent adverse events — a class effect common to FGF21 pathway agonists and GLP-1-based therapies. No additional safety signals were specifically enumerated in the published abstract. The tolerability profile, while important, did not prevent the trial from demonstrating robust efficacy at both doses, suggesting that the benefit-risk profile in the F4 MASH population is likely to support regulatory advancement.

It is important to note that the retrieved dataset does not include SYNCHRONY Phase 3 trial data, interim readouts, or regulatory submissions. The BALANCED Phase 2b results represent the highest-evidence clinical signal currently captured in this analysis. Any characterization of SYNCHRONY outcomes would go beyond the retrieved evidence.

Akero's patent estate: scope, layering, and durability to 2042

Akero Therapeutics holds at least four active US patents protecting efruxifermin's molecular architecture, with expiry dates extending from 2039 to at least 2042 — a layered IP estate that reflects a deliberate strategy of staggered filing and continuation prosecution. For any acquirer, the durability and breadth of this patent portfolio is as commercially significant as the clinical data, since it determines the exclusivity window within which a MASH franchise can be built and defended.

The patent claims across the four filings are structurally consistent but progressively refined, a hallmark of continuation prosecution strategy. The foundational patent (US11059872B1, 2021) establishes the core FGF21 variant fusion protein concept with Fc linkage, FGFBP3 binding reduction, and PREP susceptibility reduction. Subsequent filings (US11746138B2, US11879005B2) appear to be continuations of the same patent family, extending protection on the same inventive concept through different claim sets, while US20220372109A1 introduces a broader variant claim architecture covering "one or more mutations compared to a reference polypeptide" — a claim that could encompass next-generation molecules beyond the current efruxifermin scaffold.

The therapeutic indications claimed span NASH, NAFLD, type 2 diabetes, obesity, and hypertriglyceridemia — a deliberate breadth that extends the patent's commercial relevance well beyond the initial MASH regulatory filing. This indication breadth is strategically important: it creates IP coverage for combination use-cases (e.g., with GLP-1 agonists or lipid-lowering agents) and for label expansions into adjacent metabolic conditions, without requiring separate patent filings. According to WIPO data on biologic patent prosecution, indication-broad claims of this type are a standard strategy for maximising the commercial lifetime of a biologic IP estate.

Strategic implications for a post-acquisition MASH programme

An acquirer of efruxifermin inherits three commercially distinct assets: a Phase 2b-validated clinical molecule, a layered US patent estate with exclusivity to 2042, and a broad indication claim architecture that extends into the wider cardiometabolic space. The strategic challenge — and opportunity — lies in translating these assets into a coherent commercial programme in a MASH market where only two FDA-approved treatments existed as of 2024.

The F4 cirrhosis beachhead

The BALANCED trial's focus on MASH with compensated cirrhosis (F4 fibrosis) is not merely a clinical choice — it is a regulatory strategy. F4 MASH represents the highest unmet need sub-population, where disease progression to decompensated cirrhosis or hepatocellular carcinoma is most imminent and where the FDA has historically been most receptive to accelerated approval pathways based on histological surrogate endpoints. A successful Phase 3 readout in this population would establish efruxifermin as the first or one of the first approved agents for MASH cirrhosis — a commercially defensible first-mover position in a sub-indication that other MASH therapies have not yet fully addressed.

Cardiometabolic label expansion

The multi-system efficacy documented in the BALANCED trial — improvements in liver stiffness, MRI-PDFF liver fat, LDL-cholesterol, and liver function tests — alongside patent claims covering type 2 diabetes, obesity, and hypertriglyceridemia, signals a natural label expansion pathway. A post-acquisition commercial strategy could pursue sequential indication filings that leverage the same clinical data package to support labelling in metabolic comorbidities, effectively transforming a hepatology drug into a cardiometabolic franchise. This is a well-established commercial playbook in the GLP-1 space, and the FGF21 mechanism's breadth of metabolic effects — as documented in the retrieved literature — provides the scientific basis for an analogous strategy.

Combination therapy positioning

The patent estate's broad indication claims and the FGF21 mechanism's complementarity with other metabolic pathways (insulin sensitization, lipid metabolism, hepatic steatosis) create a natural framework for combination therapy development. While no formally published combination regimens pairing efruxifermin with other agents appear in the retrieved dataset, the patent claim architecture — which covers conditions directly targeted by GLP-1 agonists, SGLT2 inhibitors, and lipid-lowering agents — suggests that the IP estate was designed with combination use-cases in mind. An acquirer with existing metabolic assets could pursue combination IND strategies without requiring new IP filings.

FGF21 gene therapy as a next-generation consideration

The retrieved academic literature identifies FGF21 gene therapy as a parallel modality approaching clinical development — one that could, in principle, achieve sustained FGF21 pathway activation without the manufacturing complexity of a weekly-injected biologic. While no head-to-head or combination data with efruxifermin appear in the retrieved dataset, a post-acquisition R&D strategy would need to monitor this space. The most recent Akero patent (US11879005B2, 2024) continues to expand the variant claim landscape, suggesting that next-generation FGF21 molecule development may already be underway within the existing IP framework.

The broader competitive context is shaped by the scarcity of approved MASH treatments relative to disease prevalence. As documented in the retrieved literature, MASLD affects approximately 38% of the global population, yet the treatment landscape remains nascent. An acquirer positioning efruxifermin within this market benefits from both the regulatory tailwind of high unmet need and the scientific credibility of a Phase 2b dataset published in a top-tier hepatology journal with leading academic investigators as co-authors — a credentialing signal that matters for both payer negotiations and physician adoption. For further context on global liver disease burden, WHO and PatSnap's resources on drug discovery intelligence provide complementary perspectives on unmet need quantification in metabolic disease.